Evidence map›Paper›PMID 37815932›Full record

ArticleGlycobiology2024

Galectin-3 does not interact with RNA directly.

Egan L Peltan, Nicholas M Riley, Ryan A Flynn, David S Roberts, Carolyn R Bertozzi

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Glycobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Galectic Control of Ferroptosis?Journal of the American Society of Nephrology : JASN · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Egan L PeltanDepartment of Chemical and Systems Biology, Stanford University School of Medicine, 269 Campus Drive CCSR 4145 Stanford, CA 94305, United States.
Nicholas M RileySarafan ChEM-H, Stanford University, Stanford ChEM-H Building 290 Jane Stanford Way Stanford, CA 94305, United States.ORCID 0000-0002-1536-2966
Ryan A FlynnStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02445, United States.ORCID 0000-0001-5013-0442
David S RobertsSarafan ChEM-H, Stanford University, Stanford ChEM-H Building 290 Jane Stanford Way Stanford, CA 94305, United States.
Carolyn R BertozziSarafan ChEM-H, Stanford University, Stanford ChEM-H Building 290 Jane Stanford Way Stanford, CA 94305, United States.ORCID 0000-0003-4482-2754
Stanford University · USBoston Children's Hospital · USHoward Hughes Medical Institute · US

Funding

METABOLIC OLIGOSACCHARIDE ENGINEERINGR01GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI Carolyn Bertozzi · 1999 to 2026
$5.6M
Metabolic Engineering with Bioorthogonal Chemical ReportersR37GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERTOZZI, CAROLYN · 2009 to 2018
$4.7M
Capturing the Holistic Glycocode through Systems GlycobiologyK99GM147304 · NIGMS · STANFORD UNIVERSITY · PI RILEY, NICHOLAS M · 2022 to 2022
$100k
Howard Hughes Medical InstituteNIGMS NIH HHS K99 GM147304NIGMS NIH HHS R01 GM058867NIGMS NIH HHS R37 GM058867NIH HHS GM058867
6 · The paper itself

Abstract

Galectin-3, well characterized as a glycan binding protein, has been identified as a putative RNA binding protein, possibly through participation in pre-mRNA maturation through interactions with splicosomes. Given recent developments with cell surface RNA biology, the putative dual-function nature of galectin-3 evokes a possible non-classical connection between glycobiology and RNA biology. However, with limited functional evidence of a direct RNA interaction, many molecular-level observations rely on affinity reagents and lack appropriate genetic controls. Thus, evidence of a direct interaction remains elusive. We demonstrate that antibodies raised to endogenous human galectin-3 can isolate RNA-protein crosslinks, but this activity remains insensitive to LGALS3 knock-out. Proteomic characterization of anti-galectin-3 IPs revealed enrichment of galectin-3, but high abundance of hnRNPA2B1, an abundant, well-characterized RNA-binding protein with weak homology to the N-terminal domain of galectin-3, in the isolate. Genetic ablation of HNRNPA2B1, but not LGALS3, eliminates the ability of the anti-galectin-3 antibodies to isolate RNA-protein crosslinks, implying either an indirect interaction or cross-reactivity. To address this, we introduced an epitope tag to the endogenous C-terminal locus of LGALS3. Isolation of the tagged galectin-3 failed to reveal any RNA-protein crosslinks. This result suggests that the galectin-3 does not directly interact with RNA and may be misidentified as an RNA-binding protein, at least in HeLa where the putative RNA associations were first identified. We encourage further investigation of this phenomenon employ gene deletions and, when possible, endogenous epitope tags to achieve the specificity required to evaluate potential interactions.

Indexed as

Galectin 3RNABlood ProteinsEpitopesGalectinsHumansProteomicsRNA-Binding ProteinsBlood ProteinsEpitopesGalectin 3GalectinsLGALS3 protein, humanRNARNA-Binding ProteinsGalectin-3GALECTINShnRNPA2B1RNA-binding proteins

Identifiers

PMID37815932
PMCPMC11648975
OpenAlexW4387476193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.